The burden of hyperlipidaemia and diabetes in cardiovascular diseases

Fundamental and Clinical Pharmacology

Volumn 21, Issue SUPPL. 2, 2007, Pages 1-3

  Merkler, Marijan ^a   Reiner, Željko ^a  

^a KBC Zagreb   (Croatia)

Author keywords

Burden of disease; Coronary heart disease; Diabetes; Hypercholesterolaemia; Myocardial infarction; Risk factors

Indexed keywords

ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ACUTE CORONARY SYNDROME; ASIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COMORBIDITY; CORRELATION ANALYSIS; DAILY LIFE ACTIVITY; DIABETES MELLITUS; DISEASE ASSOCIATION; EUROPE; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; MORBIDITY; MORTALITY; PRIORITY JOURNAL; REVIEW; TRANSLUMINAL CORONARY ANGIOPLASTY;

CARDIOVASCULAR DISEASES; CORONARY DISEASE; DIABETES COMPLICATIONS; DIABETES MELLITUS; HUMANS; HYPERLIPIDEMIAS; MYOCARDIAL INFARCTION; RISK FACTORS;

EID: 36248960063     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2007.00529.x     Document Type: Review

References (18)

1. Reiner Ž., Tedeschi-Reiner E. Atherosclerosis - a paradox of Eastern European countries. Atherosclerosis (2006) 7/3 (Suppl.) 461.
2. Scholte op Reimer W., Simoons M.L., Boersma E., Gitt A.K. Cardiovascular diseases in Europe. European Society of Cardiology, Sophia Antipolis, 2006.
3. Lopez A.D., Mathers C.D., Ezzati M., Jamison D.T., Murray C.J.L. Global burden of disease and risk factors. Oxford University Press and The World Bank, New York, 2006, p. 298.
4. Law M.R., Wald N.J., Thompson S.G. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? Br. Med. J. (1994) 308 367 372.
5. Baigent C., Keech A., Kearney P.M. et al. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet (2005) 366 1267 1278.
6. Reiner Ž., Mihatov Š., Miličić D., Bergovec M., Planinc D. Treatment and secondary prevention of ischemic coronary events in Croatia (TASPIC-CRO study). Eur. J. Cardiovasc. Prev. Rehabil. (2006) 13 636 654.
7. Haffner S.M., Letho S., Ronnemaa T., Pyorala K., Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. (1998) 339 229 234.
8. Evans J.M.M., Wang J., Morris A.D. Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort studies. Br. Med. J. (2002) 324 939.
9. Becker A., Bos G., de Vegt F. et al. Cardiovascular events in type 2 diabetes: comparisom wit nondiabetic individuals without and with prior cardiovascular disease: 10-year follow-up of the Hoom Study. Eur. Heart J. (2003) 24 1406 1413.
10. Lee C.D., Folsom A.R., Pankow J.S., Brancati F.L. For the Atherosclerosis Risk in Communities (ARIC) Study Investigators. Cardiovascular events in diabetic and nondiabetic adults with or without history of myocardial infarction. Circulation (2004) 109 855 860.
11. Asia Pacific Cohort Studies Collaboration. Coronary risk prevention for those with and without diabetes. Eur. J. Cardiovasc. Prev. Rehabil. (2006) 13 30 36.
12. Collins R., Armitage J., Parish S., Sleight P., Peto R. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet (2003) 361 2005 2016.
13. Colhoun H.M., Betteridge D.J., Durrington P.N. et al. CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet (2004) 364 685 696.
14. Ryden L., Standl E., Bartnik M. et al. Guidelines on diabetes, prediabetes and cardiovascular diseases: executive summary. Eur. Heart J. (2007) 28 88 136.
15. Graham I., Atar D., Borch-Johnsen K. et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Eur. J. Cardiovasc. Prev. Rehabil. (2007) 14 (Suppl. 2) S1 S113.
16. EUROASPIRE Study Group. EUROASPIRE: a European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. Eur. Heart J. (1997) 18 1569 1582.
17. EUROASPIRE II Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: Principal results from EUROASPIRE II Euro Heart Survey Programme. Eur. Heart J. (2001) 22 554 572.
18. Bergman Marković B., Kranjčević K., Reiner Ž., Milaković Blažeković S., Stojanović Špehar S. Drug therapy of cardiovascular risk factors: guidelines versus reality in primary health care service. Croat. Med. J. (2005) 46 984 989.